Harvard Bioscience (NASDAQ:HBIO) Director Buys $41,103.75 in Stock

Harvard Bioscience, Inc. (NASDAQ:HBIO) Director William Snider acquired 8,475 shares of the firm’s stock in a transaction that occurred on Tuesday, March 17th. The shares were purchased at an average cost of $4.85 per share, for a total transaction of $41,103.75. Following the completion of the acquisition, the director owned 32,000 shares in the company, valued at $155,200. This represents a 36.03% increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

William Snider also recently made the following trade(s):

• On Monday, March 16th, William Snider bought 12,525 shares of Harvard Bioscience stock. The stock was purchased at an average cost of $4.99 per share, with a total value of $62,499.75.

Harvard Bioscience Trading Down 5.9%

HBIO stock opened at $5.27 on Friday. The company has a market capitalization of $23.56 million, a PE ratio of -0.41 and a beta of 1.51. The company has a debt-to-equity ratio of 2.61, a quick ratio of 0.41 and a current ratio of 2.20. Harvard Bioscience, Inc. has a one year low of $2.81 and a one year high of $9.50. The company’s 50 day moving average price is $5.55 and its two-hundred day moving average price is $5.66.

Institutional Investors Weigh In On Harvard Bioscience

A number of large investors have recently added to or reduced their stakes in the company. Weber Capital Management LLC ADV purchased a new position in shares of Harvard Bioscience in the fourth quarter valued at about $2,140,000. Corsair Capital Management L.P. raised its stake in shares of Harvard Bioscience by 1,008.7% during the fourth quarter. Corsair Capital Management L.P. now owns 1,108,692 shares of the medical instruments supplier’s stock valued at $741,000 after acquiring an additional 1,008,692 shares during the last quarter. Nano Cap New Millennium Growth Fund L P purchased a new stake in shares of Harvard Bioscience during the fourth quarter worth about $401,000. AMH Equity Ltd grew its stake in shares of Harvard Bioscience by 15.4% in the third quarter. AMH Equity Ltd now owns 4,047,535 shares of the medical instruments supplier’s stock worth $1,775,000 after purchasing an additional 538,832 shares during the last quarter. Finally, Meros Investment Management LP grew its stake in shares of Harvard Bioscience by 32.6% in the fourth quarter. Meros Investment Management LP now owns 1,217,628 shares of the medical instruments supplier’s stock worth $814,000 after purchasing an additional 299,369 shares during the last quarter. Institutional investors own 80.87% of the company’s stock.

Analysts Set New Price Targets

Several analysts have weighed in on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Harvard Bioscience in a research note on Monday, December 29th. New Street Research set a $6.00 price objective on Harvard Bioscience in a research note on Friday, March 13th. Zacks Research upgraded Harvard Bioscience to a “hold” rating in a report on Thursday, December 11th. Benchmark lowered their target price on Harvard Bioscience from $20.00 to $6.00 and set a “speculative buy” rating for the company in a research note on Friday, March 13th. Finally, Wall Street Zen cut Harvard Bioscience from a “buy” rating to a “hold” rating in a report on Saturday. One investment analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Harvard Bioscience presently has a consensus rating of “Hold” and an average price target of $6.00.

About Harvard Bioscience

Harvard Bioscience, Inc develops, manufactures and distributes life science research instruments and consumables used by academic, biopharmaceutical and government laboratories worldwide. The company’s product portfolio spans cellular physiology, microfluidics, electrophysiology and lab automation, providing tools that enable researchers to study everything from cell behavior and organ function to drug delivery and tissue mechanics.

Through its operating units—most notably Harvard Apparatus, BTX, Radnoti and Warner Instruments—Harvard Bioscience offers a diverse range of scientific equipment including precision pumps, stereotaxic instruments, electroporation and gene delivery systems, perfusion systems and microinjection tools.